ATE262347T1 - Verfahren zur hemmung der atrophie oder förderung der hypertrophie - Google Patents

Verfahren zur hemmung der atrophie oder förderung der hypertrophie

Info

Publication number
ATE262347T1
ATE262347T1 AT00980561T AT00980561T ATE262347T1 AT E262347 T1 ATE262347 T1 AT E262347T1 AT 00980561 T AT00980561 T AT 00980561T AT 00980561 T AT00980561 T AT 00980561T AT E262347 T1 ATE262347 T1 AT E262347T1
Authority
AT
Austria
Prior art keywords
hypertrophy
inhibiting
atrophy
inhibiting atrophy
causing
Prior art date
Application number
AT00980561T
Other languages
English (en)
Inventor
David J Glass
Christian Rommel
Sue C Bodine
George D Yancopoulos
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of ATE262347T1 publication Critical patent/ATE262347T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
AT00980561T 1999-11-23 2000-11-17 Verfahren zur hemmung der atrophie oder förderung der hypertrophie ATE262347T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16708699P 1999-11-23 1999-11-23
PCT/US2000/031845 WO2001037852A2 (en) 1999-11-23 2000-11-17 Methods of inhibiting atrophy or promoting hypertrophy

Publications (1)

Publication Number Publication Date
ATE262347T1 true ATE262347T1 (de) 2004-04-15

Family

ID=22605871

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00980561T ATE262347T1 (de) 1999-11-23 2000-11-17 Verfahren zur hemmung der atrophie oder förderung der hypertrophie

Country Status (8)

Country Link
EP (1) EP1231934B1 (de)
JP (1) JP2003514866A (de)
AT (1) ATE262347T1 (de)
AU (1) AU777546C (de)
CA (1) CA2392217A1 (de)
DE (1) DE60009333T2 (de)
NZ (1) NZ519087A (de)
WO (1) WO2001037852A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019021059A1 (en) * 2017-07-28 2019-01-31 Novartis Ag INDOLE DERIVATIVES AND USES THEREOF
CN113151502B (zh) * 2021-05-18 2022-06-03 华中农业大学 一种与猪活体产肉性状关联的遗传标记及应用
KR102942488B1 (ko) 2022-11-23 2026-03-24 숙명여자대학교산학협력단 근력 조절인자 ctrp1 단백질 및 이의 용도
WO2025045915A1 (en) * 2023-08-29 2025-03-06 Institut National de la Santé et de la Recherche Médicale Methods for inducing muscle hypertrophy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444047A (en) * 1994-06-16 1995-08-22 Dipasquale; Gene Treatment of arthritic and post-surgical orthopedic conditions with Insulin-like Growth Factor-I
JP2000502097A (ja) * 1995-12-20 2000-02-22 メディカル、リサーチ、カウンシル タンパク質合成の制御、および作用薬のスクリーニング法
US6055909A (en) * 1998-09-28 2000-05-02 Raytheon Company Electronically configurable towed decoy for dispensing infrared emitting flares
CA2335391A1 (en) * 1998-10-02 2000-04-13 Kenneth Walsh Akt compositions for enhancing survival of cells

Also Published As

Publication number Publication date
AU1780901A (en) 2001-06-04
AU777546C (en) 2005-05-19
DE60009333D1 (de) 2004-04-29
NZ519087A (en) 2004-11-26
AU777546B2 (en) 2004-10-21
DE60009333T2 (de) 2005-03-10
WO2001037852A3 (en) 2002-02-14
CA2392217A1 (en) 2001-05-31
EP1231934B1 (de) 2004-03-24
WO2001037852A2 (en) 2001-05-31
EP1231934A2 (de) 2002-08-21
JP2003514866A (ja) 2003-04-22

Similar Documents

Publication Publication Date Title
ATE277621T1 (de) Verfahren und zusammensetzungen zur prävention von toleranz von bronchodilatoren
DE50003227D1 (de) Verfahren zur verarbeitung von datenstrukturen
ATE327680T1 (de) Verfahren zur verbesserung der knochenmineralisierung
DE69941362D1 (de) Vorrichtung und verfahren zur erhaltung und/oder wiederherstellung der lebensfähigkeit von organen
DE60120520D1 (de) Verfahren zur behandlung von abwasser
DE60103085D1 (de) Verfahren zur verwaltung von resourcen
DE60002182D1 (de) Verfahren zur entsalzung von röhöl
DE69907349D1 (de) Verfahren zur Verminderung von Stress in GaN Bauelementen
DE60024306D1 (de) Verfahren zur behandlung von radioaktivem graphit
DE60101116T2 (de) Verfahren zur Nitrifikation/Denitrifikation von organischem Abwasser
DE59900006D1 (de) Verfahren zur Isolierung von gekrümmten Flächen
DE60128788D1 (de) Zusammensetzung und verfahren zur bekämpfung von pflanzenschädlichen arthropoden
DE69941821D1 (de) Fluorenthaltende zusammensetzung zur behandlung von oberflächen
DE60021960D1 (de) Verfahren zur Kompensation von Neigung und/oder Defokussierung, und Vorrichtung für dasselbige
DE50006521D1 (de) Verfahren zur aktivierung von passiviertem eisen
ATE262347T1 (de) Verfahren zur hemmung der atrophie oder förderung der hypertrophie
DE69934823D1 (de) Verfahren zur last-regulierung
DE60101333D1 (de) Verfahren zur behandlung von stickstoff- und/oder phosphor- und/oder organischen stoffen- und/oder schwermetalle enhaltendem abwasser
WO2002069890A3 (en) Methods of identifying agents affecting atrophy and hypertrophy
ATE301626T1 (de) Verfahren zur disproportionierung von isopentan
ATA61197A (de) Verfahren zur herstellung von sulfatzement oder sulfatzementzuschlagstoffen
DE50001116D1 (de) Verfahren zur justage von parabolantennen
ATE206392T1 (de) Verfahren zur alkylierug von gehinderten sulfonamiden
DE69914560D1 (de) Verfahren zur acylierung von aminoalcoholen
DE69833494D1 (de) Verfahren zur eliminierung einer stickstoff enthaltenden heterocyclischen oder aromatischen verbindung aus abwasser

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties